Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2014 Nov 7;14(1):101–110. doi: 10.1158/1535-7163.MCT-14-0094

Figure 2. Axitinib and crizotinib short term treatment in the sunitinib sensitive RP-R-01 PDX model.

Figure 2

Subcutaneous RP-R-01 bearing mice (3/group) were treated with vehicle, axitinib (36 mg/kg, 2×/day), crizotinib (25 mg/kg, 1×/day) or combination for either 2 (labeled as 2d) or 7 days (7d). Tumors were then harvested, processed, and tissue sections were stained by immunohistochemistry for (A) CD31, to display endothelial cells and (B) pimonidazole by immunofluorescence (green), to assess intra-tumor hypoxia (DAPI counterstain marks nuclei in blue). Scale bar, 50µm. Blinded quantitative analysis of (C) tumor vascularization and (D) intra-tumor hypoxia, expressed as mean percentage positive stained area ± S.E,. * p <0.05, ***p <0.001, using two tailed t-test analysis (the vertical spotted lines highlights the difference in time among groups).